Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn


We have particular strengths in our research group including:

  • Drug utilisation studies
  • Pharmacoepidemiology using large electronic health record datasets and disease registers
  • Identification and prevention of adverse drug events
  • Adherence to medication and related to health outcome
  • Disease epidemiology (breast cancer, cardiovascular disease of particular interest)
  • Population health and health services research
  • Health behaviour change methods.


Our research

HRB Research Leader Award: Statistical epidemiology in HSR and population health:(QSM)

The research programme will provide data and evidence on population based estimates and risk prediction of adverse drug events (ADEs) in the primary and secondary care settings.Three work packages are planned.

  • Work package 1: Prevalence of ADRs including a prospective study of patients admitted to hospital following an adverse drug event, and the development and testing feasibility of an intervention to reduce ADEs in primary care.
  • Work package 2: How medication taking behaviours influence health outcomes.
  • Work package 3: Epidemiological and economic modelling studies will be undertaken to estimate the frequency and burden (cost of illness) of ADEs in the Irish population.


Irish Cancer Society: Breast-Predict

The Irish Cancer Society’s first collaborative cancer research centre, BREAST-PREDICT, is co-ordinated by UCD. It takes an integrative approach to breast cancer research, across disciplines to address a number of research questions to improve the treatment and prognosis for women who develop breast cancer. The research group are responsible mainly for Work package.

2. Molecular epidemiology: Uncovering pathways from population drug exposures, comorbidities and lifestyle factors to breast cancer outcomes, which involves a prospective study of breast cancer patients enrolled through the Clinical Trials Ireland network, St James’s Hospital and Galway University Hospital. Here we aim to utilise the data and bio-resources available from the first work package (national biobank and database) to examine the effects of pre-diagnosis aspirin and statin exposure, diabetes, and obesity on breast cancer outcome.